A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries

AbstractObjective: To develop a user-friendly tool for managing the transfer of economic evaluation results. Methods: Factors that may influence the transfer of health economic study results were systematically identified and the way they impact on transferability was investigated. A transferability decision chart was developed that includes: knock out criteria; a checklist based on the transferability factors; and methods for improving transferability and for assessing the uncertainty of transferred results. This approach was tested on various international cost-effectiveness studies in the areas of interventional cardiology, vaccination and screening. Results: The transfer of study results is possible pending the outcomes of the transferability check and necessary adjustments. Transferability factors can be grouped into areas of methodological, healthcare system and population characteristics. Different levels of effort are required for analysis of factors, ranging from very low (e.g. discount rate) to very high (e.g. practice variation). The impact of differences of most transferability factors can be estimated via the key health economic determinants: capacity utilisation, effectiveness, productivity loss and returns to scale.Depending on the outcomes of the transferability check a correction of the study results for inflation and for differences related to currencies or purchasing power might be sufficient. Otherwise, modelling-based adjustments might be necessary, requiring the (re-)building and sometimes structural modification of the study model. For determination of the most essential adjustments, a univariate sensitivity analysis seems appropriate. If not all relevant study parameters can be substituted with country-specific ones, multivariate or probabilistic sensitivity analysis seems to be a promising way to quantify the uncertainty associated with a transfer. If study results cannot be transferred, the transfer of study models or designs should be investigated as this can significantly save time when conducting a new study. Conclusions: Our transferability decision chart is a transparent and user-friendly tool for assessing and improving the transferability of economic evaluation results. A state of the art description of the methodology in a study, providing detailed components for calculation, is not only essential for determining its transferability but also for improving it via modelling adjustments.

[1]  R. Baltussen,et al.  The impact of age on cost-effectiveness ratios and its control in decision making. , 1996, Health economics.

[2]  G. Stoddart,et al.  A re-examination of the meaning and importance of supplier-induced demand. , 1994, Journal of health economics.

[3]  Gillian D. Sanders,et al.  Cost Effectiveness of a Potential Vaccine for Human papillomavirus , 2003, Emerging infectious diseases.

[4]  B. Hylander,et al.  An international study of patient compliance with hemodialysis. , 1999, JAMA.

[5]  Muammar Qaddafi,et al.  The Green Book , 1975 .

[6]  A Gafni,et al.  Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? , 1996, Critical care medicine.

[7]  R. Panerai,et al.  Transferability of Health Technology Assessment with Particular Emphasis on Developing Coutries , 1988, International Journal of Technology Assessment in Health Care.

[8]  Charles E. Phelps,et al.  Good Technologies Gone Bad , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  Jacobs-van der Bruggen Mam,et al.  Aan roken toe te schrijven productiviteitskosten voor Nederlandse werkgevers in 1999 , 2002 .

[10]  A. Enthoven,et al.  Should operations be regionalized? The empirical relation between surgical volume and mortality. , 1980, The New England journal of medicine.

[11]  F. Rutten,et al.  Economic evaluation and health care decision-making. , 1996, Health policy.

[12]  S. Yusuf Variations between countries in invasive cardiac procedures , 1998, The Lancet.

[13]  L. Goldman,et al.  Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. , 1994, Circulation.

[14]  J. Caro,et al.  Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study. , 2000, Acta cardiologica.

[15]  R. Willke,et al.  Economic Analysis of Tirilazad Mesylate for Aneurysmal Subarachnoid Hemorrhage: Economic Evaluation of a Phase III Clinical Trial in Europe and Australia , 1998, International Journal of Technology Assessment in Health Care.

[16]  R. Baltussen,et al.  Making cost assessments based on RCTs more useful to decision-makers. , 1996, Health policy.

[17]  K. Schulman,et al.  Differences in care-seeking behavior for acute chest pain in the United States and Japan. , 2004, American heart journal.

[18]  C. Wolfe,et al.  A COMPARISON OF THE COST-EFFECTIVENESS OF STROKE CARE PROVIDED IN LONDON AND COPENHAGEN , 2000, International Journal of Technology Assessment in Health Care.

[19]  S. Reske,et al.  Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography , 2000, European Journal of Nuclear Medicine.

[20]  Nazmi Sari,et al.  Do competition and managed care improve quality? , 2002, Health economics.

[21]  Antonio Colombo,et al.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.

[22]  D. Elliott Costing intensive care services: a review of study methods, results and limitations. , 1997, Australian critical care : official journal of the Confederation of Australian Critical Care Nurses.

[23]  H S Luft,et al.  Effects of Surgeon Volume and Hospital Volume on Quality of Care in Hospitals , 1987, Medical care.

[24]  P Carlsson,et al.  Resource costing for multinational neurologic clinical trials: methods and results. , 1998, Health economics.

[25]  M A Koopmanschap,et al.  Analysis of costs and cost-effectiveness in multinational trials. , 2001, Health policy.

[26]  A. Tonkin Issues in extrapolating from clinical trials to clinical practice and outcomes. , 1998, Australian and New Zealand journal of medicine.

[27]  A. Haycox,et al.  Customising an International Disease Management Model to the Needs of Individual Countries , 2012, PharmacoEconomics (Auckland).

[28]  R. Leidl Some Factors to Consider when Using the Results of Economic Evaluation Studies at the Population Level , 1994, International Journal of Technology Assessment in Health Care.

[29]  R. Brooks,et al.  EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise. , 1991, Health policy.

[30]  R. Willke,et al.  Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.

[31]  M F Drummond,et al.  Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues , 1991, International Journal of Technology Assessment in Health Care.

[32]  M. Dougados,et al.  Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries , 2002, Annals of the rheumatic diseases.

[33]  W. Edmunds,et al.  Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  Daniel Polsky,et al.  Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries? , 2003, Health economics.

[35]  Timing of adoption of laparoscopic cholecystectomy in Denmark and in The Netherlands: a comparative study. , 2001, Health policy.

[36]  M. Koopmanschap,et al.  A Practical Guide for Calculating Indirect Costs of Disease , 1996, PharmacoEconomics.

[37]  Regina E. Herzlinger,et al.  Market Driven Health Care: Who Wins, Who Loses in the Transformation of America's Largest Service Industry , 1996 .

[38]  N. Ikegami,et al.  Estimating an EQ-5D population value set: the case of Japan. , 2002, Health economics.

[39]  Banz,et al.  New Perspectives on the Cost-Effectiveness of Palmaz-Schatzª Coronary Stenting, Balloon Angioplasty, and Coronary Artery Bypass Surgery. , 1997, The Journal of invasive cardiology.

[40]  B. O'brien,et al.  A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. , 1997, The American journal of managed care.

[41]  V. Ho Learning and the evolution of medical technologies: the diffusion of coronary angioplasty. , 2002, Journal of health economics.

[42]  Banz,et al.  Cost-Effectiveness of Palmaz-Schatzª Stenting in Patients with Coronary Artery Disease in Germany. , 1997, The Journal of invasive cardiology.

[43]  M. R. Mölken,et al.  Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma , 1998, PharmacoEconomics.

[44]  W. Stason Cost-Effectiveness Analysis in Health Care: Opportunities and Challenges to International Comparisons , 1990 .

[45]  M. Drummond,et al.  Issues in the Cross-National Assessment of Health Technology , 1992, International Journal of Technology Assessment in Health Care.

[46]  W. Greiner,et al.  The transferability of international economic health-economic results to national study questions , 2000, HEPAC Health Economics in Prevention and Care.

[47]  P. Danzon,et al.  Cross-national price differences for pharmaceuticals: how large, and why? , 2000, Journal of health economics.

[48]  T. Weiss,et al.  How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? , 2001, Diabetes care.

[49]  A. Mason,et al.  The Generalisability of Pharmacoeconomic Studies , 2012, PharmacoEconomics.

[50]  W. Greiner,et al.  Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation , 2009, Medizinische Klinik.

[51]  R. Lawrence,et al.  COMMITTEE TO STUDY PRIORITIES FOR VACCINE DEVELOPMENT , 2000 .

[52]  P. Pattynama,et al.  International differences in health care costs in Europe and the United States: Do these affect the cost-effectiveness of diagnostic strategies for pulmonary embolism? , 1999, European Radiology.

[53]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[54]  D Menon,et al.  Canadian Coordinating Office for Health Technology Assessment. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[55]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[56]  Andrew H. Briggs,et al.  Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.

[57]  E. Topol,et al.  In-hospital costs associated with new percutaneous coronary devices. , 1991, The American journal of cardiology.

[58]  B. O'brien,et al.  Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? , 1996, Medical care.

[59]  ANALYZING DIFFERENCES IN THE COSTS OF TREATMENT ACROSS CENTERS WITHIN ECONOMIC EVALUATIONS , 2001, International Journal of Technology Assessment in Health Care.

[60]  S Greenfield,et al.  Variations in resource utilization among medical specialties and systems of care. Results from the medical outcomes study. , 1992, JAMA.

[61]  M. Weinstein,et al.  Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. , 1993, Journal of the American College of Cardiology.

[62]  S. Normand,et al.  Does prospective payment reduce inpatient length of stay? , 2002, Health economics.

[63]  John Nixon,et al.  Can economic evaluations be made more transferable? , 2005, The European Journal of Health Economics.

[64]  M. Drummond,et al.  A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis , 1996, International Journal of Technology Assessment in Health Care.

[65]  M. Kretzschmar,et al.  Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. , 2001, American journal of epidemiology.

[66]  John Urquhart,et al.  Pharmacoeconomic Consequences of Variable Patient Compliance With Prescribed Drug Regimens , 1999, PharmacoEconomics.

[67]  T Philip,et al.  Analysis of the eligibility of published economic evaluations for transfer to a given health care system. Methodological approach and application to the French health care system. , 1999, Health policy.

[68]  農林水産奨励会農林水産政策情報センター,et al.  The green book : appraisal and evaluation in central government , 2003 .

[69]  Jeffrey A. Alexander,et al.  Managed care and technical efficiency in outpatient substance abuse treatment units , 1998, The Journal of Behavioral Health Services & Research.

[70]  P. Beutels,et al.  Economic Evaluation of Vaccination , 2012, PharmacoEconomics.

[71]  Alain C Enthoven,et al.  Should operations be regionalized? The empirical relation between surgical volume and mortality. 1979. , 1979, Clinical orthopaedics and related research.

[72]  E. Nord,et al.  EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway. , 1991, Health policy.

[73]  Banz,et al.  Cost-Effectiveness of Palmaz-Schatzª Stenting in Patients with Coronary Artery Disease in The Netherlands. , 1997, The Journal of invasive cardiology.

[74]  S. Yusuf,et al.  Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation , 1998, The Lancet.

[75]  Harold S. Luft,et al.  Association of volume with outcome of coronary artery bypass graft surgery —scheduled vs nonscheduled operations , 1987, JAMA.

[76]  M A Koopmanschap,et al.  The friction cost method for measuring indirect costs of disease. , 1995, Journal of health economics.

[77]  W. Manning,et al.  Moral Hazard and Consumer Incentives in Health Care , 2000 .

[78]  H. Luft,et al.  The volume-outcome relationship: practice-makes-perfect or selective-referral patterns? , 1987, Health services research.

[79]  H. Luft The Relation Between Surgical Volume and Mortality: An Exploration of Causal Factors and Alternative Models , 1980, Medical care.

[80]  S Bryan,et al.  Extrapolation of Cost-Effectiveness Information to Local Settings , 1998, Journal of health services research & policy.

[81]  R. Baltussen,et al.  Real World Designs in Economic Evaluation , 1999, PharmacoEconomics.

[82]  P E Fine,et al.  Herd immunity: history, theory, practice. , 1993, Epidemiologic reviews.

[83]  F. Antoñanzas Transferability of Economic Evaluation Results , 2012, PharmacoEconomics.

[84]  R Axelsson,et al.  Financial incentives in health care. The impact of performance-based reimbursement. , 2001, Health policy.

[85]  N. Powe,et al.  Methodological Hurdles in Conducting Pharmacoeconomic Analyses , 1999, PharmacoEconomics.

[86]  Taghreed Adam,et al.  COST-EFFECTIVENESS ANALYSIS: CAN WE REDUCE VARIABILITY IN COSTING METHODS? , 2003, International Journal of Technology Assessment in Health Care.

[87]  H. D. de Koning,et al.  How cost-effective is breast cancer screening in different EC countries? , 1993, European journal of cancer.

[88]  Diane O. Dunet,et al.  Variation in Average Costs among Federally Sponsored State-Organized Cancer Detection Programs: Economies of Scale? , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[89]  G. Tognoni,et al.  Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. , 1996, Archives of internal medicine.

[90]  S Greenfield,et al.  Variations in resource utilization among medical specialties and systems of care. , 1995, Annual review of public health.

[91]  H. Krumholz,et al.  In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. , 1995, Circulation.

[92]  J C Jager,et al.  Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. , 2000, Sexually transmitted diseases.

[93]  N. Black,et al.  Outcome of Total Hip Replacement in Japan and England: Comparison of Two Retrospective Cohorts , 1998, International Journal of Technology Assessment in Health Care.

[94]  D. Revicki,et al.  Pharmacoeconomic Evaluation in the Real World , 1999, PharmacoEconomics.

[95]  M. Gold Cost-effectiveness in health and medicine , 2016 .